187 related articles for article (PubMed ID: 25305747)
1. IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort.
Markkula A; Simonsson M; Ingvar C; Rose C; Jernström H
BMC Cancer; 2014 Oct; 14():759. PubMed ID: 25305747
[TBL] [Abstract][Full Text] [Related]
2. Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.
Markkula A; Simonsson M; Rosendahl AH; Gaber A; Ingvar C; Rose C; Jernström H
Int J Cancer; 2014 Oct; 135(8):1898-910. PubMed ID: 24599585
[TBL] [Abstract][Full Text] [Related]
3. Association of Estrogen Receptor Alpha and Interleukin 6 Polymorphisms with Lymphovascular Invasion, Extranodal Extension, and Lower Disease-Free Survival in Thai Breast Cancer Patients.
Sa-Nguanraksa D; Suntiparpluacha M; Kulprom A; Kummalue T; Chuangsuwanich T; Avirutnan P; O-Charoenrat P
Asian Pac J Cancer Prev; 2016; 17(6):2935-40. PubMed ID: 27356714
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients.
Korobeinikova E; Myrzaliyeva D; Ugenskiene R; Raulinaityte D; Gedminaite J; Smigelskas K; Juozaityte E
BMC Genet; 2015 Jun; 16():70. PubMed ID: 26112140
[TBL] [Abstract][Full Text] [Related]
5. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.
Lei J; Rudolph A; Moysich KB; Rafiq S; Behrens S; Goode EL; Pharoah PP; Seibold P; Fasching PA; Andrulis IL; Kristensen VN; Couch FJ; Hamann U; Hooning MJ; Nevanlinna H; Eilber U; Bolla MK; Dennis J; Wang Q; Lindblom A; Mannermaa A; Lambrechts D; García-Closas M; Hall P; Chenevix-Trench G; Shah M; Luben R; Haeberle L; Ekici AB; Beckmann MW; Knight JA; Glendon G; Tchatchou S; Alnæs GI; Borresen-Dale AL; Nord S; Olson JE; Hallberg E; Vachon C; Torres D; Ulmer HU; Rüdiger T; Jager A; van Deurzen CH; Tilanus-Linthorst MM; Muranen TA; Aittomäki K; Blomqvist C; Margolin S; Kosma VM; Hartikainen JM; Kataja V; Hatse S; Wildiers H; Smeets A; Figueroa J; Chanock SJ; Lissowska J; Li J; Humphreys K; Phillips KA; ; Linn S; Cornelissen S; van den Broek SA; Kang D; Choi JY; Park SK; Yoo KY; Hsiung CN; Wu PE; Hou MF; Shen CY; Teo SH; Taib NA; Yip CH; Ho GF; Matsuo K; Ito H; Iwata H; Tajima K; Dunning AM; Benitez J; Czene K; Sucheston LE; Maishman T; Tapper WJ; Eccles D; Easton DF; Schmidt MK; Chang-Claude J
Breast Cancer Res; 2015 Feb; 17(1):18. PubMed ID: 25849327
[TBL] [Abstract][Full Text] [Related]
6. Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk.
Slattery ML; Curtin K; Sweeney C; Wolff RK; Baumgartner RN; Baumgartner KB; Giuliano AR; Byers T
Obesity (Silver Spring); 2008 Feb; 16(2):339-47. PubMed ID: 18239642
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
8. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
[TBL] [Abstract][Full Text] [Related]
9. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
10. Effects of Infection-Induced Fever and the Interaction with IL6 rs1800796 Polymorphism on the Prognosis of Breast Cancer.
Ye H; Tang LY; Liang ZZ; Chen QX; Li YQ; Liu Q; Xie X; Lin Y; Ren ZF
Cancer Epidemiol Biomarkers Prev; 2022 Nov; 31(11):2030-2037. PubMed ID: 36084325
[TBL] [Abstract][Full Text] [Related]
11. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
[TBL] [Abstract][Full Text] [Related]
12. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
13. Association of angiogenesis and inflammation-related gene functional polymorphisms with early-stage breast cancer prognosis.
Korobeinikova E; Ugenskiene R; Insodaite R; Rudzianskas V; Jaselske E; Poskiene L; Juozaityte E
Oncol Lett; 2020 Jun; 19(6):3687-3700. PubMed ID: 32391092
[TBL] [Abstract][Full Text] [Related]
14. Predictors of time to death after distant recurrence in breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
[TBL] [Abstract][Full Text] [Related]
15. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
Mulligan AM; Couch FJ; Barrowdale D; Domchek SM; Eccles D; Nevanlinna H; Ramus SJ; Robson M; Sherman M; Spurdle AB; Wappenschmidt B; Lee A; McGuffog L; Healey S; Sinilnikova OM; Janavicius R; Hansen Tv; Nielsen FC; Ejlertsen B; Osorio A; Muñoz-Repeto I; Durán M; Godino J; Pertesi M; Benítez J; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Cattaneo E; Bonanni B; Viel A; Pasini B; Papi L; Ottini L; Savarese A; Bernard L; Radice P; Hamann U; Verheus M; Meijers-Heijboer HE; Wijnen J; Gómez García EB; Nelen MR; Kets CM; Seynaeve C; Tilanus-Linthorst MM; van der Luijt RB; van Os T; Rookus M; Frost D; Jones JL; Evans DG; Lalloo F; Eeles R; Izatt L; Adlard J; Davidson R; Cook J; Donaldson A; Dorkins H; Gregory H; Eason J; Houghton C; Barwell J; Side LE; McCann E; Murray A; Peock S; Godwin AK; Schmutzler RK; Rhiem K; Engel C; Meindl A; Ruehl I; Arnold N; Niederacher D; Sutter C; Deissler H; Gadzicki D; Kast K; Preisler-Adams S; Varon-Mateeva R; Schoenbuchner I; Fiebig B; Heinritz W; Schäfer D; Gevensleben H; Caux-Moncoutier V; Fassy-Colcombet M; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Hardouin A; Berthet P; Muller D; Fricker JP; Mortemousque I; Pujol P; Coupier I; Lebrun M; Kientz C; Longy M; Sevenet N; Stoppa-Lyonnet D; Isaacs C; Caldes T; de la Hoya M; Heikkinen T; Aittomäki K; Blanco I; Lazaro C; Barkardottir RB; Soucy P; Dumont M; Simard J; Montagna M; Tognazzo S; D'Andrea E; Fox S; Yan M; Rebbeck T; Olopade O; Weitzel JN; Lynch HT; Ganz PA; Tomlinson GE; Wang X; Fredericksen Z; Pankratz VS; Lindor NM; Szabo C; Offit K; Sakr R; Gaudet M; Bhatia J; Kauff N; Singer CF; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Mai PL; Greene MH; Imyanitov E; O'Malley FP; Ozcelik H; Glendon G; Toland AE; Gerdes AM; Thomassen M; Kruse TA; Jensen UB; Skytte AB; Caligo MA; Soller M; Henriksson K; Wachenfeldt vA; Arver B; Stenmark-Askmalm M; Karlsson P; Ding YC; Neuhausen SL; Beattie M; Pharoah PD; Moysich KB; Nathanson KL; Karlan BY; Gross J; John EM; Daly MB; Buys SM; Southey MC; Hopper JL; Terry MB; Chung W; Miron AF; Goldgar D; Chenevix-Trench G; Easton DF; Andrulis IL; Antoniou AC; ; ; ; ; ; ; ;
Breast Cancer Res; 2011; 13(6):R110. PubMed ID: 22053997
[TBL] [Abstract][Full Text] [Related]
16. Genotypic and haplotype analysis of Interleukin-6 and -18 gene polymorphisms in association with clinicopathological factors in breast cancer.
Padala C; Puranam K; Shyamala N; Kupsal K; Kummari R; Galimudi RK; Gundapaneni KK; Tupurani MA; Suryadevera A; Chinta SK; Manavathi B; Hanumanth SR
Cytokine; 2022 Dec; 160():156024. PubMed ID: 36182709
[TBL] [Abstract][Full Text] [Related]
17. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States.
Slattery ML; Curtin K; Baumgartner R; Sweeney C; Byers T; Giuliano AR; Baumgartner KB; Wolff RR
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):747-55. PubMed ID: 17416766
[TBL] [Abstract][Full Text] [Related]
18. Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer.
DeMichele A; Gray R; Horn M; Chen J; Aplenc R; Vaughan WP; Tallman MS
Cancer Res; 2009 May; 69(10):4184-91. PubMed ID: 19435922
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival.
Boyapati SM; Shu XO; Ruan ZX; Cai Q; Smith JR; Wen W; Gao YT; Zheng W
Clin Cancer Res; 2005 Feb; 11(3):1093-8. PubMed ID: 15709176
[TBL] [Abstract][Full Text] [Related]
20. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
